Cardiovascular disease (CVD) is the leading cause of death in the United States and the world. Heart failure commonly results from irreparable damage to the myocardial tissue, frequently from a myocardial infarction (heart attack). Innovation in regenerative medicine and stem cell therapy has provided optimism towards repairing tissue and reversing myocardial injuries. However, stem cell therapies have failed to produce durable functional recovery. Over the past 17+ years there has been 300+ clinical trials involving stem cells for the treatment of heart disease (clinicaltrial.gov). There are currently 0 FDA approved cell therapies for cardiac indications. While many cell types and delivery methods have been tested in these trials, one commonality remains; therapeutic cells are not retained in the heart.